Hvivo (HVO)

Sector:

Health Care

Index:

FTSE AIM All-Share

27.25p
   
  • Change Today:
    -0.25p
  • 52 Week High: 30.50p
  • 52 Week Low: 14.25p
  • Currency: UK Pounds
  • Shares Issued: 680.37m
  • Volume: 601,061
  • Market Cap: £185.40m

Open Orphan signs deal with Empiric Logic to complete Health Data platform

By Josh White

Date: Tuesday 15 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Europe-focussed rare and orphan drug consulting services platform provider Open Orphan has signed a new strategic collaboration agreement with Empiric Logic, it announced on Tuesday, to build on the earlier work it had performed, and complete the build out of its 'Health Data' platform as Europe's first rare disease, advocacy-led genomic database.
The AIM-traded firm said Empiric Logic - a managed software service company which provides software to the life sciences, pharmaceuticals, pharma services and biotechnology sectors - would incorporate its propriety, privacy preserving, and artificial intelligence-enabled software into Open Orphan's Health Data platform, to aid the collection and management capabilities of the software.

It said the collaboration was the final stage in the completion of its Genomic Health Data platform, and would speed up its launch.

The platform built on the genomic analysis, database architecture know-how and prior professional experience between the founders of Empiric Logic and Open Orphan's chief commercial officer Maurice Treacy.

"This is an exciting step towards the completion of our genomic Health Data platform, and we are delighted to have Empiric on board to help us quickly and securely become one of the largest databases of rare disease patients in Europe," said Open Orphan chief executive officer Cathal Friel.

Gareth O'Sullivan, CEO at Empiric Logic, added that his company was "delighted" to be supporting the Open Orphan team with the final steps of preparing the Genomic Health Data platform to accept its first data.

"As part of the rollout of the Open Orphan database, it will be making substantial use of our artificial intelligence capabilities, such as for identification of rare-disease genetic mutations, but also for the potential identification of patients for clinical trials going forward," O'Sullivan explained.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Hvivo Market Data

Currency UK Pounds
Share Price 27.25p
Change Today -0.25p
% Change -0.91 %
52 Week High 30.50p
52 Week Low 14.25p
Volume 601,061
Shares Issued 680.37m
Market Cap £185.40m

Hvivo Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.51% below the market average95.51% below the market average95.51% below the market average95.51% below the market average95.51% below the market average
81.25% below the sector average81.25% below the sector average81.25% below the sector average81.25% below the sector average81.25% below the sector average
Price Trend
96.18% above the market average96.18% above the market average96.18% above the market average96.18% above the market average96.18% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income
94.72% below the market average94.72% below the market average94.72% below the market average94.72% below the market average94.72% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
41.80% above the market average41.80% above the market average41.80% above the market average41.80% above the market average41.80% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average

What The Brokers Say

Strong Buy 3
Buy 3
Neutral 0
Sell 0
Strong Sell 0
Total 6
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Hvivo Dividends

  Latest Previous
  Final Special
Ex-Div 18-Apr-24 04-May-23
Paid 20-May-24 09-Jun-23
Amount 0.20p 0.45p

Trades for 16-May-2024

Time Volume / Share Price
16:29 10,000 @ 27.24p
16:29 2,000 @ 27.24p
16:17 366 @ 27.28p
16:09 6,250 @ 27.28p
16:05 56,100 @ 27.00p

Hvivo Key Personnel

CEO Yamin Mo' Khan

Top of Page